Vardenafil (Levitra/Staxyn) Side Effects: Potentially Permanent Adverse Events Explained

What Are the Most Common Side Effects of Vardenafil?

Most people who take vardenafil at the standard 10 mg dose experience mild, short-lived side effects driven by its mechanism of action: smooth-muscle relaxation through PDE5 inhibition and the resulting vasodilation. In the pooled Phase III trials submitted to the FDA, headache occurred in roughly 15% of patients, flushing in 11%, rhinitis in 9%, and dyspepsia in 4% at 10 mg. These rates rose modestly at 20 mg and fell at 5 mg. [1]

Headache and Flushing

Both headache and flushing are direct pharmacodynamic effects. Vasodilation of cerebral and cutaneous vessels produces the symptoms. They typically resolve within 2 to 4 hours as plasma concentrations fall. Reducing the dose to 5 mg often cuts the frequency meaningfully.

Dyspepsia and Nasal Congestion

PDE5 is expressed in the lower esophageal sphincter and nasal mucosa. Vardenafil's inhibition there relaxes smooth muscle and can produce acid reflux symptoms or nasal stuffiness. Both effects are transient and respond to dose reduction.

Visual Changes (Transient Blue-Tinge)

A small fraction of patients (less than 2% in trials) report transient color tinge, blurred vision, or increased light sensitivity. PDE6, an enzyme involved in phototransduction, shares structural homology with PDE5 and is inhibited to a lesser degree by all PDE5 inhibitors. This effect is temporary and resolves as the drug clears. [2]

Potentially Permanent Side Effect 1: Non-Arteritic Ischemic Optic Neuropathy (NAION)

NAION is a stroke of the optic nerve. It produces sudden, painless, usually monocular vision loss and may result in a permanent visual field defect. The FDA added a warning about NAION to all PDE5 inhibitor labels in 2005 after receiving post-market reports across the drug class. [3]

What the Evidence Shows

The causal link between vardenafil specifically and NAION is difficult to establish because erectile dysfunction and NAION share many of the same risk factors: diabetes, hypertension, hyperlipidemia, coronary artery disease, and a small optic disc cup-to-disc ratio (so-called "disc at risk"). A case series published in the Journal of Neuro-Ophthalmology identified that most patients who developed NAION while taking a PDE5 inhibitor had at least one of these pre-existing risk factors. [4]

A 2014 analysis in JAMA Internal Medicine (N=38,177 men) found that current use of PDE5 inhibitors was associated with a 2-fold increased odds of NAION compared with non-use (OR 2.15, 95% CI 1.06 to 4.34). [5] The absolute risk remains low given the baseline incidence of NAION (approximately 2 to 10 per 100,000 men aged 50 and older per year), but the potential for permanent visual loss makes this the most serious ophthalmic concern with vardenafil.

Who Is at Highest Risk

Men with a prior episode of NAION in one eye are at elevated risk for involvement of the second eye. The current FDA-approved labeling for Levitra states: "Physicians should advise patients to stop use of all PDE5 inhibitors, including VARDENAFIL, and seek medical attention immediately in the event of sudden loss of vision in one or both eyes." [1]

Clinical Instruction

Any sudden, painless decrease in vision during or after vardenafil use is a medical emergency. Patients must stop the drug immediately and present to an ophthalmologist or emergency department the same day.

Potentially Permanent Side Effect 2: Priapism and Erectile Dysfunction

Priapism is a prolonged, painful erection unrelated to sexual stimulation. It is a urological emergency. An erection lasting more than 4 hours causes progressive hypoxia and acidosis in penile tissue; one lasting more than 6 hours carries a high risk of permanent corporal fibrosis, which can result in irreversible erectile dysfunction (ED) and, in severe cases, penile deformity. [6]

Incidence Data

Vardenafil-associated priapism is rare. The FDA Adverse Event Reporting System (FAERS) database contains post-market reports for the entire PDE5 inhibitor class, and the Levitra prescribing information lists priapism under post-marketing adverse events without providing a precise frequency, classifying it as "not known" given the limits of spontaneous reporting. [1]

The mechanism is physiologically consistent: PDE5 inhibition prolongs cGMP-mediated smooth-muscle relaxation in the corpus cavernosum. In men with sickle cell disease, sickle cell trait, leukemia, multiple myeloma, or anatomical penile conditions, the risk of priapism is amplified because venous outflow is already compromised. [6]

Conditions That Raise Risk

• Sickle cell disease or trait
• Multiple myeloma or leukemia
• Polycythemia vera
• Penile anatomical abnormalities

Men with any of these conditions should discuss this risk specifically before starting vardenafil. A 2021 review in the Journal of Sexual Medicine noted that PDE5 inhibitors remain contraindicated as routine therapy in patients with sickle cell disease who have recurrent stuttering priapism, though evidence-based guidelines for that subset continue to evolve. [7]

Time-Critical Response

An erection lasting more than 2 hours that does not resolve warrants a call to a physician. One lasting more than 4 hours is a urological emergency requiring aspiration of blood from the corpora and, if needed, intracorporal injection of a sympathomimetic agent such as phenylephrine. Delay beyond 6 hours significantly worsens prognosis for erectile function recovery.

Potentially Permanent Side Effect 3: Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss (SSNHL) is defined as a loss of 30 dB or more across three consecutive frequencies over a 72-hour period. The FDA added a warning about SSNHL to all PDE5 inhibitor labels in October 2007, based on case reports accumulated through FAERS. [8]

Mechanism and Evidence

PDE5 is expressed in the stria vascularis of the cochlea, and it may regulate cochlear blood flow. A case report series and a pharmacovigilance analysis identified temporal associations between PDE5 inhibitor dosing and SSNHL onset in some patients, though a population-level causal analysis remains confounded by the high background incidence of idiopathic SSNHL in middle-aged men, the same demographic most likely to use vardenafil. [9]

A 2020 systematic review and meta-analysis in Laryngoscope (7 studies, N=more than 1.5 million patient-years of follow-up combined across the studies) reported a statistically significant association between PDE5 inhibitor use and SSNHL (pooled OR approximately 1.8, though confidence intervals varied across included studies). The authors recommended caution in patients with prior hearing loss. [10]

What to Watch For

Patients should stop vardenafil and call their physician immediately if they experience sudden decrease or loss of hearing, hearing loss in one ear only, or hearing loss accompanied by tinnitus or dizziness. The FDA-approved labeling states this explicitly. [1] SSNHL has a narrow treatment window: high-dose oral corticosteroids initiated within 72 hours of onset (and ideally within 24 hours) offer the best chance of partial or full recovery. Delay means the hearing loss may become permanent.

Cardiovascular Adverse Events: Serious but Usually Not Permanent

Vardenafil produces a mean maximum decrease in supine systolic blood pressure of approximately 7 mmHg and a mean maximum decrease in supine diastolic blood pressure of approximately 8 mmHg in healthy volunteers at the 10 mg dose. [1] In patients taking antihypertensives, the additive effect can be clinically significant.

Nitrate Contraindication

The most dangerous cardiovascular interaction is with nitrate drugs. Vardenafil potentiates the hypotensive effect of organic nitrates through synergistic cGMP elevation. The FDA considers co-administration absolutely contraindicated. Men who use short-acting nitrates (sublingual nitroglycerin) for angina must not take vardenafil. If a patient taking vardenafil develops chest pain requiring nitrate therapy, emergency providers should be informed of the last vardenafil dose because the interaction can persist for at least 24 hours after the drug's elimination. [1]

QTc Prolongation

Vardenafil prolongs the cardiac QT interval in a dose-dependent fashion. In a thorough QT study conducted as part of the regulatory filing, vardenafil 10 mg produced a mean QTc prolongation of 8 milliseconds; at 80 mg (four times the maximum dose), the prolongation was 10 milliseconds. The FDA label includes a specific warning against use in patients with congenital long QT syndrome or in patients taking Class IA or Class III antiarrhythmics (e.g., quinidine, amiodarone). [1] QT-related arrhythmias may be reversible once the drug is stopped, but they carry a risk of sudden cardiac death if they culminate in torsades de pointes.

Drug Interactions That Amplify Side Effect Risk

CYP3A4 Inhibitors

Vardenafil is primarily metabolized by CYP3A4 and, to a lesser extent, CYP2C9. Strong CYP3A4 inhibitors substantially raise vardenafil plasma concentrations and extend its duration. Ketoconazole 400 mg once daily increased vardenafil AUC by 9-fold in a pharmacokinetic study cited in the label. The FDA-approved maximum dose when used with ketoconazole 400 mg is 2.5 mg per 72 hours. Ritonavir increased vardenafil AUC 49-fold and is listed as a contraindication. [1]

Alpha-Blockers

Alpha-adrenergic antagonists used for benign prostatic hyperplasia (tamsulosin, terazosin, doxazosin) or hypertension add to vardenafil's blood-pressure-lowering effect. Tamsulosin 0.4 mg combined with vardenafil 5 mg produced no clinically significant augmentation of blood pressure lowering in dedicated interaction studies. Doxazosin, however, has produced symptomatic hypotension with vardenafil; the label recommends caution and starting at the lowest vardenafil dose. [1]

Special Populations With Elevated Risk Profiles

Men Over Age 65

Older men clear vardenafil more slowly. A pharmacokinetic study in men aged 65 years and older showed a 52% increase in AUC compared with men aged 18 to 45 years. The starting recommended dose in men over 65 is 5 mg. [1] Side effects related to vasodilation, orthostatic hypotension, and drug interactions are more consequential in this population.

Hepatic Impairment

Child-Pugh Class B hepatic impairment increased vardenafil AUC by 160% compared to healthy controls. The maximum recommended dose in that group is 5 mg. Vardenafil is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) because it has not been adequately studied. [1]

Men With Pre-Existing Eye Disease

Men with a prior NAION episode, retinitis pigmentosa, or other hereditary degenerative retinal diseases should discuss vardenafil use carefully with both their prescribing physician and an ophthalmologist. The FDA label explicitly recommends caution in patients with a "crowded disc" anatomy. [1]

Rare Side Effects: Full Spectrum From the FDA Label and FAERS

The section below covers rare events listed in post-marketing surveillance, where frequency cannot be determined reliably from spontaneous reports.

Neurological

Seizures, transient global amnesia, and migraine have been reported as post-market events. The mechanism for transient global amnesia is speculative but may involve cerebral vasodilation in susceptible individuals. One review in Neurological Sciences documented case reports of transient global amnesia following PDE5 inhibitor use, with symptoms resolving within 24 hours in all documented cases. [11]

Hematological

Epistaxis (nosebleed) occurs in a small number of patients, likely reflecting PDE5-mediated vasodilation in the nasal mucosa. Leukopenia and anemia appear in the FAERS record but without established causation.

Dermatological

Stevens-Johnson syndrome, a potentially fatal skin reaction, has been reported in post-market surveillance for the PDE5 inhibitor class, though causation has not been definitively established given polypharmacy in nearly all reported cases.

Penile Tissue

Beyond priapism, some patients report penile pain without prolonged erection. The clinical significance is unclear, and no structural damage has been attributed to this symptom in the literature reviewed.

The framework below summarizes how clinicians at HealthRX stratify patients by risk before prescribing vardenafil. This is based on our clinical team's synthesis of FDA label guidance, the 2018 ACC/AHA recommendations on sexual activity in patients with cardiovascular disease, and the prescribing patterns documented in our patient cohort.

HealthRX Vardenafil Risk Stratification Framework

| Risk Tier | Patient Profile | Recommended Action | |---|---|---| | Low | No cardiovascular disease, no nitrates, no prior NAION or SSNHL, no sickle cell disease | Standard dosing 10 mg; standard counseling | | Moderate | Age over 65, or hepatic impairment Class B, or alpha-blocker use, or multiple CV risk factors | Start 5 mg; review all concomitant medications; blood pressure check before initiation | | High | Prior NAION in one eye, active cardiac ischemia, systolic BP <90 mmHg, any nitrate use, HIV on ritonavir | Vardenafil likely contraindicated; consult cardiology or ophthalmology before prescribing | | Do Not Prescribe | Any nitrate use, ritoiguat, Child-Pugh C, history of torsades de pointes | Contraindicated per FDA label |

What Patients Should Report Immediately

Any of the following events after taking vardenafil requires stopping the drug and seeking same-day emergency or urgent medical care:

• Sudden decrease or loss of vision in one or both eyes
• Sudden decrease or loss of hearing, possibly with tinnitus or dizziness
• An erection lasting more than 2 to 4 hours
• Chest pain, dizziness, or fainting, especially if combined with nitrate use
• Irregular or rapid heartbeat

The FDA-approved medication guide distributed with Levitra and Staxyn lists each of these as warning signs for serious adverse events. [1]

How Vardenafil Compares to Other PDE5 Inhibitors for Side Effects

Sildenafil (Viagra), tadalafil (Cialis), and avanafil (Stendra) share the same class-level risks for NAION, priapism, and SSNHL because all inhibit PDE5 through the same mechanism. Vardenafil is the most potent inhibitor of PDE5 among the approved agents on a molar basis, with an IC50 for PDE5 of approximately 0.14 nM compared to sildenafil's 3.7 nM, though this laboratory difference does not translate directly to greater clinical side-effect frequency at approved doses. [12]

Vardenafil's QTc prolongation signal is more pronounced than that of sildenafil and tadalafil in dedicated QT studies. A comparative analysis cited in the FDA's pharmacology review noted that tadalafil and sildenafil produced smaller mean QTc changes than vardenafil at their respective therapeutic doses. This is one reason prescribers sometimes choose an alternative agent for men with borderline QTc intervals on baseline ECG.

Tadalafil's 17.5-hour half-life means a missed interaction (e.g., a patient who forgot they took it and later uses a nitrate) can create a prolonged hazard window. Vardenafil's 4-to-5-hour half-life shortens that window, which some clinicians consider a practical safety advantage.